PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
William M. Yashar, Itallia V. Pacentine, Akram Taherinasab, Thai Nguyen, Samantha J. Worme, Mitsuhiro Tsuchiya, Theresa A. Lusardi, Chelsea Hutchinson, Thomas Fillmore, Camilo Posso, Sara J.C. Gosline, Paul Piehowski, Galip Gürkan Yardımcı, Andrew Adey, Julia E. Maxson, Theodore P. Braun
This study identifies stem-monocytic AML as a distinct subtype resistant to venetoclax and shows that PU.1 inhibition synergizes with BCL2 blockade to enhance therapeutic response.
bioRxiv · Jan 23, 2026 · PreprintCancer Biology